Updated: 03/2019
PARP Approved: 04/2019

Prior Authorization Criteria

Supprelin LA (histrelin acetate)

All requests for Supprelin LA (histrelin acetate) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

For all requests for Supprelin LA (histrelin acetate) all of the following criteria must be met:

- Documentation showing the member has tried and failed or had an intolerance or contraindication to leuprolide acetate (Lupron Depot)*
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines

Coverage may be provided with a diagnosis of central precocious puberty (CPP) when the following criteria is met:

- Current age ≤ 11 for females and ≤ 12 for males
- Must meet all of the following diagnostic criteria:
    - Baseline LH and FSH in pubertal range
    - A pubertal response to GnRH stimulation test
    - Advanced bone age (≥2 standard deviations above the gender/age related mean or bone age at least 1 year greater than chronological age)
    - Neuro-imaging (CT or MRI) to rule out intracranial tumor
    - Adrenal steroid levels to exclude congenital adrenal hyperplasia
    - If a male, human chorionic gonadotropin level to rule out a chorionic gonadotropin secreting tumor
- Onset of secondary sexual characteristics occurred at age < 8 years for females and <9 years for males
- **Initial Duration of Approval:** 12 months
- **Reauthorization criteria:**
    - Current age ≤ 11 years old for females or ≤ 12 years old for males
    - Documentation of a physical exam in the past year with evaluation of growth and pubertal development
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided with a diagnosis of gender dysphoria to suppress puberty in an adolescent if the following criteria are met:

- The adolescent has demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed)
- Co-existing psychological, medical, or social problems that could interfere with treatment (e.g. that may compromise treatment adherence) have been addressed, such that the adolescent's situation and function are stable enough to start treatment
- The adolescent has given informed consent and, particularly when the adolescent has not reached the age of medical consent, the parents or other caretakers or guardians have consented to the treatment and are involved in supporting the adolescent throughout the treatment process. When parental consent cannot be obtained, exceptions will be reviewed on a case by case basis and in conjunction with the prescriber.
- Documentation of laboratory testing to monitor the safety of continuous hormone therapy

- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria:**
    - Documentation indicating stability or improvement in gender dysphoria
- **Reauthorization Duration of Approval:** 12 months

*Lupron Depot may require prior authorization

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

Updated: 03/2019
PARP Approved: 04/2019

SUPPRELIN LA (histrelin acetate)
PRIOR AUTHORIZATION FORM – PAGE 1 of 2

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway Health℠ Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative.
PHONE: (800) 392-1147 Monday through Friday 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:
Gateway ID:	Member weight: _____pounds or _____kg

REQUESTED DRUG INFORMATION

Medication:	Strength:
Frequency:	Duration:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:

Billing Information

This medication will be billed: ☐ at a pharmacy **OR**
☐ medically (if medically please provide a JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:

☐ Central precocious puberty (CPP), ICD-10: _____
- What age was the onset of secondary sexual characteristics? _____
- Is baseline LH and FSH in pubertal range? ☐ Yes ☐ No
- Was there a pubertal response to a GnRH stimulation test? ☐ Yes ☐ No
- Does the member have advanced bone age? ☐ Yes ☐ No
- Has neuro-imaging been done? ☐ Yes ☐ No
- Have adrenal steroid levels been checked? ☐ Yes ☐ No
- If male, has human chorionic gonadotropin level been checked? ☐ Yes ☐ No

☐ Gender dysphoria, ICD-10: _____
- Is this being used to suppress puberty in an adolescent? ☐ Yes ☐ No
- Has the adolescent demonstrated a long-lasting and intense pattern of gender nonconformity or gender dysphoria (whether suppressed or expressed)? ☐ Yes ☐ No
- Have co-existing psychological, medical, or social problems that could interfere with treatment been addressed such that the adolescent's situation and function are stable enough to start treatment? ☐ Yes ☐ No
- Has the adolescent, parent, or other caretaker/guardian given informed consent? ☐ Yes ☐ No
- Has baseline lab monitoring been done? ☐ Yes ☐ No

☐ Other: _____, ICD-10: _____

Has Lupron Depot been tried? ☐ Yes ☐ No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

*** Form is continued on next page ***

Updated: 03/2019
PARP Approved: 04/2019

SUPPRELIN LA (histrelin acetate) **PRIOR AUTHORIZATION FORM (CONTINUED)– PAGE 2 of 2**	
Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Gateway Health℠ Pharmacy Services. **FAX:** (888) 245-2049 If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Monday through Friday 8:30am to 5:00pm	
MEMBER INFORMATION	
Member Name:	DOB:
Gateway ID:	Member weight: _____pounds or _____kg
REAUTHORIZATION	
Central precocious puberty (CPP): Did member have a physical exam in the past year with evaluation of growth and pubertal development? ☐ Yes ☐ No	
Gender Dysphoria: Has the member experienced stability or improvement as a result of treatment? ☐ Yes ☐ No	
SUPPORTING INFORMATION or CLINICAL RATIONALE	
Prescribing Provider Signature	Date